📊 AZN Key Takeaways
Is Astrazeneca PLC (AZN) a Good Investment?
Unable to conduct fundamental analysis due to unavailable SEC financial data. The company shows only 1 metric available with no data freshness information, preventing assessment of profitability trends, financial health, or growth quality.
AstraZeneca’s latest SEC filing shows high-quality fundamental momentum, with 2025 revenue up to $58.7 billion from $54.1 billion, operating profit rising to $13.7 billion from $10.0 billion, and net income increasing to $10.2 billion from $7.0 billion. Cash generation remains strong, with operating cash flow of $14.6 billion supporting R&D, bolt-on acquisitions, and shareholder returns, although the balance sheet still carries meaningful debt and a very large intangible asset base.
Why Buy Astrazeneca PLC Stock? AZN Key Strengths
- No strengths identified
- Strong top-line and earnings growth, with double-digit expansion in product sales over the last two years and a sharp improvement in operating leverage in 2025
- Excellent profitability profile, including gross profit of $48.1 billion on $58.7 billion of revenue and materially higher net income and EPS year over year
- Robust cash generation and improving financial flexibility, with operating cash flow of $14.6 billion, lower year-end borrowings than 2024, and higher equity
AZN Stock Risks: Astrazeneca PLC Investment Risks
- Critical data unavailability - no income statement metrics
- No balance sheet data for liquidity or solvency assessment
- No cash flow information to evaluate operational efficiency
- Insufficient data freshness and completeness for reliable analysis
- High dependence on pipeline execution, product launches, and patent durability in a pharmaceutical business where setbacks can materially affect growth
- Large goodwill and intangible asset balance from acquisitions increases impairment risk and means a substantial portion of assets is not hard capital
- Leverage remains meaningful, with total interest-bearing borrowings near $29.6 billion and continued cash commitments for contingent consideration, legal matters, and business development
Key Metrics to Watch
- Revenue and net income trends
- Operating and net margins
- Free cash flow and capital allocation
- Debt-to-equity ratio and interest coverage
- Return on equity and return on assets
- Reported product sales growth and operating profit margin
- Operating cash flow versus business development and intangible asset spending
Astrazeneca PLC (AZN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
AZN Profit Margin, ROE & Profitability Analysis
AZN vs Healthcare Sector: How Astrazeneca PLC Compares
How Astrazeneca PLC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Astrazeneca PLC Stock Overvalued? AZN Valuation Analysis 2026
Based on fundamental analysis, Astrazeneca PLC has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Astrazeneca PLC Balance Sheet: AZN Debt, Cash & Liquidity
AZN Revenue Growth, EPS Growth & YoY Performance
AZN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Astrazeneca PLC (CIK: 0000901832)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AZN
What is the AI rating for AZN?
Astrazeneca PLC (AZN) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 44% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AZN's key strengths?
Claude: . ChatGPT: Strong top-line and earnings growth, with double-digit expansion in product sales over the last two years and a sharp improvement in operating leverage in 2025. Excellent profitability profile, including gross profit of $48.1 billion on $58.7 billion of revenue and materially higher net income and EPS year over year.
What are the risks of investing in AZN?
Claude: Critical data unavailability - no income statement metrics. No balance sheet data for liquidity or solvency assessment. ChatGPT: High dependence on pipeline execution, product launches, and patent durability in a pharmaceutical business where setbacks can materially affect growth. Large goodwill and intangible asset balance from acquisitions increases impairment risk and means a substantial portion of assets is not hard capital.
What is AZN's revenue and growth?
Astrazeneca PLC reported revenue of N/A.
Does AZN pay dividends?
Astrazeneca PLC does not currently pay dividends.
Where can I find AZN SEC filings?
Official SEC filings for Astrazeneca PLC (CIK: 0000901832) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AZN's EPS?
Astrazeneca PLC has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AZN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Astrazeneca PLC has a BUY rating with 44% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is AZN stock overvalued or undervalued?
Valuation metrics for AZN: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AZN stock in 2026?
Our dual AI analysis gives Astrazeneca PLC a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AZN's free cash flow?
Astrazeneca PLC's operating cash flow is N/A, with capital expenditures of N/A.
How does AZN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).